Bevacizumab as Treatment for Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2014
At a glance
- Drugs Bevacizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Roche
- 05 Mar 2014 New source identified and integrated (ClinicalTrials.gov; NCT02079519).
- 18 Apr 2009 Status changed from recruiting to discontinued as reported by Roche.
- 06 Jun 2006 New trial record.